MBB Public Markets I LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• MBB Public Markets I LLC acquired 476 shares of Regeneron Pharmaceuticals, valued at approximately $302,000 in Q1, 2023.
• Analysts have varied opinions on REGN, with price targets ranging from $695.00 to $890.00, reflecting a consensus rating of "Moderate Buy."
• Regeneron recently reported a quarterly EPS of $12.89, significantly exceeding analysts' expectations and indicating a 3.6% increase in revenue year-over-year.

MBB Public Markets I LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 476 shares of the biopharmaceutical company's stock, valued at approximately $302,000.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock valued at $1,379,467,000 after buying an additional 89,579 shares during the period. Amundi grew its stake in Regeneron Pharmaceuticals by 3.4% in the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock worth $979,794,000 after purchasing an additional 52,166 shares during the period. Goldman Sachs Group Inc. grew its stake in Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after purchasing an additional 174,056 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after purchasing an additional 226,952 shares during the period. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Morgan Stanley reissued an "overweight" rating and issued a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Rothschild & Co Redburn initiated coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 target price on the stock. Sanford C. Bernstein raised their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. Finally, Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Stock Down 1.4%

NASDAQ REGN traded down $8.20 on Friday, reaching $560.00. 602,540 shares of the stock traded hands, compared to its average volume of 916,851. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a fifty day moving average price of $564.61 and a 200-day moving average price of $578.77. The company has a market cap of $59.35 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 1.87 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the company posted $11.56 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.